secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000719135-24-000036
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q2 revenue falls 10% to $12.1M; net loss widens; updates FY2024 guidance
--------------------------------------------------------------------------------

- Revenue $12.1M (-10% YoY); Advanced Energy -17% to $9.8M, OEM +29% to $2.4M.
- Net loss $6.6M ($0.19/share) vs $1.0M loss in Q2 2023; prior year had $2.7M sale-leaseback gain.
- Adjusted EBITDA loss $4.3M, up 166% from $1.6M loss in Q2 2023.
- FY2024 revenue guidance narrowed to $50.6-52.1M (from $49.7-52.9M); net loss guided $23.5-24.5M (improved).
- Stavros Vizirgianakis appointed Chairman effective May 7, 2024, succeeding retiring Andrew Makrides.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000036/0000719135-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000036/apyx-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000719135-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer